Saturday 17 October 2026
Export ENLV’s income statement to Excel — free account
Enlivex Ltd.
ENLV Healthcare Biotechnology
In the quarter to June 2026, EPS grew 5,185.1% and free cash flow grew 35.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.21
0.01
−4.55%
Follow ENLV
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
5.46 | 13.09 | 9.09 | 2.75 | 8.72 | 18.32 | 7.92 | 5.57 | 6.84 | 193.24 |
Net Debt/EBITDA |
0.62 | 4.31 | 1.89 | 1.57 | 3.83 | 4.20 | 1.84 | 0.96 | 1.51 | 118.29 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.70% | 1.24% | 5.66% | 6.20% | 0.00% | 1.08% | 0.02% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.03 | 0.01 | 0.06 | 0.07 | 0.00 | 0.01 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.97 | 0.72 | 0.65 | 0.75 | 0.93 | 1.21 | 0.77 | 0.81 | 0.87 | (0.01) |
Capex/Depreciation |
(0.47) | (1.57) | (3.81) | (0.92) | (3.56) | (2.98) | (10.45) | (0.12) | 0.15 | (0.20) |
Interest Coverage |
(176.29) | (5.87) | (1,766.33) | (8.59) | (43.49) | (3.38) | (30.89) | — | — | — |
| (120.33%) | (38.50%) | (56.96%) | (91.71%) | (50.56%) | (24.01%) | (43.78%) | (66.88%) | (55.95%) | 126.17% | |
| (102.88%) | (31.93%) | (47.64%) | (65.64%) | (40.83%) | (21.35%) | (38.16%) | (55.65%) | (46.54%) | 104.94% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (191.41%) | (149.41%) | (664.68%) | (2,533.16%) | (4.78%) |
Return on Tangible Assets |
(184.56%) | (36.57%) | (49.85%) | (84.62%) | (33.56%) | (17.17%) | (55.87%) | (99.40%) | (65.80%) | 71.23% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(582.86) | (10.65) | (15.47) | (12.53) | (13.69) | (16.09) | (26.14) | (19.07) | (9.45) | (3.44) |
Cash per Share |
371.35 | 39.41 | 41.76 | 23.41 | 41.98 | 70.62 | 40.95 | 22.05 | 17.17 | 570.50 |
Shareholders Equity per Share |
327.03 | 37.17 | 41.46 | 19.56 | 40.40 | 71.38 | 46.33 | 24.28 | 17.24 | 634.85 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
327.03 | 37.17 | 41.46 | 19.56 | 40.40 | 71.38 | 46.33 | 24.28 | 17.24 | 634.85 |
Free Cash Flow |
(15.50) | (2.43) | (3.62) | (7.23) | (12.03) | (19.17) | (32.07) | (23.63) | (12.93) | (10.48) |
Working Capital |
8.61 | 8.42 | 9.15 | 10.44 | 33.75 | 81.72 | 45.72 | 27.70 | 22.19 | 1,734.16 |
Capital Expenditures |
(0.02) | (0.13) | (0.46) | (0.19) | (1.02) | (1.62) | (8.12) | (0.10) | 0.08 | (0.07) |
Net Current Asset Value |
8.61 | 8.07 | 8.95 | 10.14 | 33.25 | 76.34 | 41.53 | 27.02 | 21.90 | 1,351.13 |
| Other line items | ||||||||||
Quick Ratio |
5.46 | 13.07 | 8.84 | 2.59 | 8.44 | 17.83 | 7.60 | 4.51 | 6.18 | 192.75 |
Depreciation/Fixed assets |
0.54 | 0.21 | 0.18 | 0.32 | 0.19 | 0.22 | 0.08 | 0.54 | 0.87 | 0.92 |
Cash ROIC |
(83.46%) | (13.91%) | (18.59%) | (28.82%) | (16.50%) | (10.98%) | (28.82%) | (41.16%) | (27.28%) | (0.29%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(582.18) | (10.08) | (13.50) | (12.20) | (12.53) | (14.73) | (19.52) | (18.99) | (9.51) | (3.42) |
Capex per Share |
(0.68) | (0.57) | (1.97) | (0.33) | (1.16) | (1.36) | (6.62) | (0.08) | 0.06 | (0.02) |
Average Receivables |
0.86 | 0.38 | 0.15 | 1.11 | — | — | — | — | — | — |
Average Payables |
1.06 | 0.37 | 0.11 | 0.24 | 0.39 | 0.67 | 1.41 | 1.39 | 0.82 | 2.31 |
Average Assets |
15.57 | 10.09 | 10.29 | 14.30 | 28.96 | 67.75 | 81.39 | 52.24 | 32.26 | 1,177.34 |
Average Common Equity |
13.32 | 8.36 | 8.61 | 10.23 | 23.38 | 60.26 | 70.94 | 43.46 | 26.84 | 979.27 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026